Tocilizumab Promising for sJIA

You Might Also Like:

• FDA Approves Subcutaneous Tocilizumab for Ages 2–17
• E6011 & Tocilizumab Monotherapy Studies Show Promising Results for RA Patients
• Rheumatology Drug Updates: Abaloparatide Promising for Osteoporosis, Plus Secukinumab for Ankylosing Spondylitis
• Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector